ALKS - Alkermes Plc logo

ALKS

Alkermes Plc

Alkermes plc develops and commercializes biopharmaceuticals for psychiatric and neurological disorders, including products for opioid and alcohol dependence, schizophrenia, and bipolar I. Its key offerings include injectables and oral medications for various conditions.

โš•๏ธ Healthcare NASDAQ Listed 1991 $ USD
$1,000 invested 30 years ago โ†’$7,248today

Score Overview

1 Year
Score
Net Growth-72.64%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth12.99%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score5.6
Net Growth237.27%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth42.08%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth131.72%
Net Trend60%
Net Income Consistency
Rev Growth123.64%
Rev Trend60%
Revenue Consistency
20 Years
Score3.8
Net Growth-60.40%
Net Trend40%
Net Income Consistency
Rev Growth6x
Rev Trend65%
Revenue Consistency
30 Years
Score
Net Growth7x
Net Trend47%
Net Income Consistency
Rev Growth53x
Rev Trend63%
Revenue Consistency
All Time
Score
Net Growth264.90%
Net Trend49%
Net Income Consistency
Rev Growth175x
Rev Trend66%
Revenue Consistency

See the full market ranking โ†’

Alkermes Plc fundamental performance

Between 2020 and 2025, revenue grew from $ 1.03B to $ 1.47B and net income went from -$ 110M to $ 241M. Revenue increased in 2 of those 5 years; net income in 2.

Across Alkermes Plc's full reported history, from 1991 to 2025, revenue grew from $ 9M to $ 1.47B and net income went from -$ 40M to $ 241M. Revenue increased in 66% of the years measured; net income in 49%.

Alkermes Plc currently holds a 20-year HDB Score of 3.8 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 50.28โ€”
1 Year2025-08-12
$ 27.4383.30%
5 Years2021-08-12
$ 28.9673.62%
10 Years2016-08-12
$ 46.677.74%
20 Years2006-08-11
$ 16.00214.25%
30 Years1996-08-12
$ 6.947x
All Time1991-07-16
$ 5.509x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 1.66B$ 66M$ 656M
2025$ 1.47B$ 241M$ 1.31B
2024$ 1.55B$ 367M$ 751M
2023$ 1.66B$ 355M$ 773M
2022$ 1.11B-$ 158M$ 608M
2021$ 1.17B-$ 48M$ 536M
2020$ 1.03B-$ 110M$ 635M
2019$ 1.17B-$ 196M$ 534M
2018$ 1.09B-$ 139M$ 539M
2017$ 903M-$ 157M$ 590M
2016$ 745M-$ 208M$ 619M
2015$ 628M-$ 227M$ 798M
2014$ 618M-$ 30M$ 801M
2013$ 432M$ 17M
2012$ 575M$ 24M$ 221M
2011$ 575M$ 24M$ 190M
2010$ 389M-$ 113M$ 201M
2009$ 186M-$ 45M$ 281M
2008$ 178M-$ 39M$ 238M
2007$ 326M$ 130M$ 341M
2006$ 240M$ 166M$ 511M
2005$ 239M$ 9M$ 351M
2004$ 166M$ 3M$ 202M
2003$ 76M-$ 75M$ 78M
2002$ 39M-$ 102M$ 165M
2001$ 47M-$ 106M$ 157M
2000$ 54M-$ 61M$ 199M
1999$ 56M-$ 16M$ 302M
1998$ 22M-$ 68M$ 152M
1997$ 33M-$ 41M$ 170M
1996$ 31M-$ 12M$ 85M
1995$ 19M-$ 18M$ 42M
1994$ 15M-$ 13M$ 1M
1993$ 12M-$ 11M$ 2M
1992$ 7M-$ 17M$ 300K
IPO1991$ 9M-$ 40M$ 3M

Explore beyond ALKS

You're looking at Alkermes Plc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies